The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Biodegradable vascular scaffold: is optimal expansion the key to minimising flow disturbances and risk of adverse events?
EuroIntervention 2015;10:1139-1142 published online ahead of print November 2014. DOI: 10.4244/EIJY14M11_09
Nicolas Foin1*, MSc, PhD; Ryo Torii2, MSc, PhD; Alessio Mattesini3, MD; Philip Wong1, MD; Carlo Di Mario4, MD, PhD
1. National Heart Centre Singapore, Singapore; 2. University College London, London, United Kingdom; 3. Department of Heart and Vessels, AOUC Careggi, Florence, Italy; 4. BRU, Royal Brompton NHS Trust and Imperial College London, London, United Kingdom
Bioresorbable vascular scaffold (BVS) use in clinical practice for the treatment of coronary lesions has expanded rapidly since they became commercially available. Recently, reports of clinical outcomes with BVS in a broader, more complex “real-world” patient population have started to emerge1-3. In a multicentre retrospective registry published recently in EuroIntervention, Capodanno and colleagues1 studied 1,189 patients in whom the Absorb BVS (Abbott Vascular, Santa Clara, CA, USA) was used in routine practice (GHOST-EU registry). They found a target lesion failure (TLF) rate of 4.4% at six months, and the incidence of definite/probable scaffold thrombosis was substantial, with rates of 1.5% at 30 ...